However, comprehensive mutation testing of LZTR1, SMARCB1, and NF2 using DNA derived from blood and different tumour samples of the patient is the method of choice to distinguish between the two conditions (Castellanos et al. 2015; Smith et al. 2016). This evidence concerns the gene LZTR1 and neoplasm.